Boehringer Ingelheim loses parasite control patent appeal

The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent

24 May 2022 The Federal Court of Australia has refused an appeal request in a decade-long case brought by Boehringer Ingelheim Animal Health against MSD subsidiary, Intervet International.

Americas

Merck & Co to buy $1bn stake in Seattle Genetics

16 September 2020 Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.

Big Pharma

Partial win for Mylan as Fed Circuit cancels Boehringer patents

17 March 2020 The US Court of Appeals for the Federal Circuit has rescued one Boehringer Ingelheim patent, covering a type 2 diabetes treatment, from invalidation but affirmed a New Jersey district court’s cancellation of two others.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Boehringer Ingelheim loses parasite control patent appeal

More on this story

Editor's picks

Editor's picks

More features